Literature DB >> 14675086

Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome.

C H van Ommen1, H Heijboer, E J van den Dool, B A Hutten, M Peters.   

Abstract

To learn more about the frequencies of congenital prothrombotic disorders in pediatric venous thromboembolism (VTE) and the outcome of this disease, we evaluated consecutive patients from 0 to 18 years with objectively diagnosed VTE at a single tertiary center over a 12-year period. We included 100 patients, with a median age at diagnosis of 1.0 year (range 2 days to 17 years). At least one underlying clinical condition was present in 96% of the patients. Factor (F)V G1691A mutation was present in 13%, FII G20210A mutation in 3%, antithrombin deficiency in 1%, protein C deficiency in 1% and protein S deficiency in 1% of the tested patients. Combined defects were present in 2.6% of the 77 patients with a complete work-up. Positive family history appeared to be the only predictor for positive testing for congenital disorders (OR 14.9, 95% CI 1.9-113). The overall mortality rate was 20%. The cumulative recurrence-free survival was 92% after 1 year of follow-up, and 82% after 7 years. The incidence and severity of the post-thrombotic syndrome was analyzed in a subgroup of 33 patients with VTE of the lower extremities. Twenty-three (70%) patients developed PTS: moderate in three and mild in 20 patients. In conclusion, congenital prothrombotic disorders seem to play a role in the development of pediatric VTE, and the risk of complications of this disease is high.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675086     DOI: 10.1046/j.1538-7836.2003.00465.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  17 in total

1.  Phlegmasia cerulea dolens in a teenage boy found to have Factor V Leiden.

Authors:  Emily Junck; Sachita Shah
Journal:  BMJ Case Rep       Date:  2015-04-02

Review 2.  How I treat venous thrombosis in children.

Authors:  Marilyn J Manco-Johnson
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

Review 3.  Duration of anticoagulant therapy in pediatric venous thromboembolism: Current approaches and updates from randomized controlled trials.

Authors:  Cristina Tarango; Sam Schulman; Marisol Betensky; Neil A Goldenberg
Journal:  Expert Rev Hematol       Date:  2017-12-17       Impact factor: 2.929

4.  In Children with Provoked Venous Thromboembolism, Increasing Plasma Coagulability during the First 3 Months Postdiagnosis is Prognostic of Recurrence.

Authors:  Marisol Betensky; M Gail Mueller; Ernest K Amankwah; Neil A Goldenberg
Journal:  Thromb Haemost       Date:  2020-05-05       Impact factor: 5.249

Review 5.  Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors.

Authors:  Neil A Goldenberg; Marco P Donadini; Susan R Kahn; Mark Crowther; Gili Kenet; Ulrike Nowak-Göttl; Marilyn J Manco-Johnson
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

6.  Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients.

Authors:  Sarah E Leary; Virginia L Harrod; Pedro A de Alarcon; Ulrike M Reiss
Journal:  J Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.289

7.  A case of panic to pulmonary embolism.

Authors:  Mansum Ng; Nikila Pandya; Brendon Conry; Richard Gale
Journal:  BMJ Case Rep       Date:  2015-06-12

Review 8.  [Prevention of perioperative venous thromboembolism in children].

Authors:  Werner Streif
Journal:  Wien Med Wochenschr       Date:  2009-10

9.  A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children.

Authors:  Neil A Goldenberg; Janette D Durham; R Knapp-Clevenger; Marilyn J Manco-Johnson
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

10.  Developing a pediatric endovascular thrombolysis program: a single-center experience.

Authors:  Kamlesh Kukreja; Ralph Gruppo; Ranjit Chima; Ross Ristagno; John Racadio
Journal:  Pediatr Radiol       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.